Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers
Standard
Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers. / Melling, Nathaniel; Bachmann, Kai; Hofmann, Bianca; El Gammal, Alexander Tarek; Reeh, Matthias; Mann, Oliver; Moebius, Christoph; Blessmann, Marco; Izbicki, Jakob Robert; Grupp, Katharina.
in: J CANCER RES CLIN, Jahrgang 145, Nr. 4, 04.2019, S. 873-879.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers
AU - Melling, Nathaniel
AU - Bachmann, Kai
AU - Hofmann, Bianca
AU - El Gammal, Alexander Tarek
AU - Reeh, Matthias
AU - Mann, Oliver
AU - Moebius, Christoph
AU - Blessmann, Marco
AU - Izbicki, Jakob Robert
AU - Grupp, Katharina
PY - 2019/4
Y1 - 2019/4
N2 - INTRODUCTION: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies.MATERIALS AND METHODS: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens.RESULTS: While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225).CONCLUSIONS: In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.
AB - INTRODUCTION: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies.MATERIALS AND METHODS: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens.RESULTS: While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225).CONCLUSIONS: In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers, Tumor/biosynthesis
KW - Carcinoma, Non-Small-Cell Lung/metabolism
KW - Female
KW - Humans
KW - Immunohistochemistry
KW - Lung Neoplasms/metabolism
KW - Male
KW - Middle Aged
KW - Neoplasm Staging
KW - Prevalence
KW - RNA-Binding Proteins/biosynthesis
KW - Tissue Array Analysis
U2 - 10.1007/s00432-019-02850-1
DO - 10.1007/s00432-019-02850-1
M3 - SCORING: Journal article
C2 - 30758670
VL - 145
SP - 873
EP - 879
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 4
ER -